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Antibiotic therapy has drastically reduced the mortality and sequelae of bacterial infections. 33 
From naturally-occurring to chemically-synthesised, different classes of antibiotics have been 34 
successfully used without detailed knowledge of how they affect bacterial dynamics in vivo. 35 
However, a proportion of patients receiving antimicrobial therapy develop recrudescent 36 
infections post-treatment. Relapsing infections are attributable to incomplete clearance of 37 
bacterial populations following antibiotic administration; the metabolic profile of this 38 
antibiotic-recalcitrant bacterial subpopulation, the spatiotemporal context of its emergence and 39 
the variance of antibiotic-bacterial interactions in vivo remain unclear. Here, we develop and 40 
apply a mechanistic mathematical model to data from a study comparing the effects of 41 
ciprofloxacin and ampicillin on the within-host dynamics of Salmonella enterica serovar 42 
Typhimurium in murine infections. Using the inferential capacity of our model, we show that 43 
the antibiotic-recalcitrant bacteria following ampicillin, but not ciprofloxacin, treatment belong 44 
to a non-replicating phenotype. Aligning with previous studies, we independently estimate that 45 
the lymphoid tissues and spleen are important reservoirs of non-replicating bacteria. Finally, 46 
we predict that post-treatment the progenitors of the non-growing and growing bacterial 47 
populations replicate and die at different rates. Ultimately, the liver, spleen and mesenteric 48 
lymph nodes are all repopulated by progenitors of the previously non-growing phenotype in 49 
















1. Introduction 64 
 65 
In the modern era, antibiotics are the cornerstone of therapeutics in bacterial disease treatment 66 
[1]. The term “antibiotics” refers to a heterogeneous collection of naturally-derived or 67 
chemically synthesised compounds which clear bacterial infections through various 68 
biochemical mechanisms, including inhibition of cell wall synthesis, bacterial lysis, nucleic 69 
acid and protein synthesis inhibition (reviewed in [2]). Antibiotics are traditionally classified 70 
as either bactericidal reducing bacterial load by killing bacteria, bacteriostatic acting to limit 71 
bacterial loads by keeping bacteria in a stationary growth phase, or both [3-4]. 72 
 73 
The effect of different antibiotics on bacterial dynamics has been studied extensively in vitro, 74 
in optimally and homogeneously growing bacterial populations harvested from exponentially 75 
growing cultures [5]. Conclusions drawn from these studies provide insights into the mode of 76 
action of different antibiotic agents on their bacterial targets; however, their clinical relevance 77 
remains unknown, as in vivo bacterial populations are characterised by heterogeneity in their 78 
growth and dissemination dynamics [6-9]. Upon successful colonisation, in vivo bacterial 79 
behaviour is multifactorially shaped by nutrient availability [6,10], host immunity [11-13], 80 
spatial arrangement of the infectious foci [14], and host cell composition in the immediate 81 
bacterial vicinity [15-16]. The landscape of within-host bacterial dynamics is further 82 
complicated by the induction of stress responses in bacterial populations exposed to antibiotics, 83 
which alter the bacterial metabolic and transcriptional profile, slow down or stop replication, 84 
and ultimately affect the pathogen’s susceptibility to the antibiotic [17]. These adaptations may 85 
lead to incomplete clearance of the bacterial load as a result of the emergence of an antibiotic-86 
recalcitrant, yet genetically non-resistant, bacterial subpopulation, termed “persister” [18-19].  87 
 88 
An important caveat of in vitro studies using optimally growing bacteria from exponential 89 
phase cultures is disregarding the influence of the bacterial growth rate on the therapeutic effect 90 
of some classes of antibiotics. All clinically-used antibiotic classes exert their maximum 91 
therapeutic effect when applied to optimally growing bacteria, where cidal agents clear 99.9% 92 
of the bacterial load under clinically relevant regimens [20-22]. However, in vitro studies with 93 
Escherichia coli and Staphylococcus aureus have revealed that even though different antibiotic 94 
classes are homogeneously effective on exponential phase bacteria, they exert heterogeneous 95 
effects on slowly-replicating and non-replicating bacterial populations. Depending on which 96 
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bacterial functions they target, different antibiotic classes are more or less active against slow- 97 
or non-replicating bacteria [5, 23-25].  98 
 99 
For example, beta-lactam antibiotics (natural and synthetic penicillin-like compounds), like 100 
ampicillin, have a range of pharmacological targets including bacterial cell wall synthesis and 101 
bacterial autolysis pathways amongst others [26], resulting in both bacteriostatic and 102 
bactericidal properties respectively. However, bacteriostatic effects attributable to bacterial cell 103 
wall disruption may act antagonistically to the bactericidal effects due to bacterial lysis [26]. 104 
This antagonistic relationship has been experimentally observed in vitro as a positive 105 
correlation between the cidal effect of beta-lactams and the growth status of the targeted 106 
bacteria [27-28]. This class of antibiotics induces structural changes in the bacterial 107 
peptidoglycan cell wall leading to cell lysis via a bulge-mediated process [29]; whether these 108 
morphological changes modulate bacterial replication rates and to what extent this 109 
phenotypically static effect antagonises the cidal action of the drug requires further 110 
investigation [30]. 111 
 112 
In contrast, quinolones, like ciprofloxacin, predominantly target the transcriptional machinery 113 
of the bacteria, and thus do not slow down bacterial growth at clinically relevant concentrations 114 
[31]. They act as DNA gyrase inhibitors, stalling bacterial chromosome replication through the 115 
formation of double-strand DNA breaks, thus preventing the replication forks from accessing 116 
the terminus [32]. Unlike beta-lactams whose efficacy has been linearly correlated with 117 
bacterial growth rate [27-28], quinolones act on heterogeneously growing bacteria so long as 118 
they remain transcriptionally active [33]. Unlike other antibiotics the bactericidal activity of 119 
ciprofloxacin is not affected by the bacterial growth rate, both in in vitro optimally-growing 120 
bacterial populations and in in vivo bacterial populations displaying heterogeneity in replication 121 
rates [23]. 122 
 123 
Unlike bacteria in cultures, the heterogeneity of bacterial growth dynamics in vivo is far greater. 124 
A substantial body of literature has been dedicated to studying the in vivo effects of 125 
antimicrobial therapy on murine infections with Salmonella enterica serovar Typhimurium, 126 
especially focusing on slow- or non-replicating bacterial cells during antibiotic exposure. 127 
Despite the fundamental in vitro differences in the modes of action of different antibiotic 128 
classes, a large proportion of in vivo experimental studies involving naturally-occurring 129 
heterogeneously-replicating bacterial populations have been conducted using second-130 
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generation fluoroquinolone agents (either enrofloxacin or ciprofloxacin) in murine infections 131 
with S. Typhimurium [6, 34-35]. Using fluorescent-based techniques for observation of 132 
bacterial dynamics at the single-cell level, these studies have identified the lymphoid tissues 133 
and the spleen as sites of highest persister concentration [34], have tried to address the 134 
replication dynamics of persisters’ progenitors [6, 34], have provided insights in the inter-organ 135 
bacterial exchange during the gastrointestinal phase of infection [35], and have studied 136 
antibiotic-driven persistence in the context of cooperative virulence [36] and promotion of 137 
antibiotic resistance [37].  138 
 139 
A later study by Rossi et al., 2017 [38] used clinically-relevant concentrations of both a beta-140 
lactam and a second-generation fluoroquinolone antibiotic later in the infection process (72 141 
hours post-inoculation) to qualitatively characterise and compare the effect of the antibiotics 142 
on the within-host Salmonella dynamics, thus providing a blueprint for using murine infections 143 
with Isogenic Tagged Strains (ITS) to address questions on the effects of antibiotic therapy on 144 
bacterial dynamics in vivo.  145 
 146 
Differences in the experimental design of these studies, including timing, dose, route of 147 
antibiotic administration, tissues examined and experimental techniques have unravelled 148 
different facets of the effects of antibiotic therapy on different tissues, as summarised in table 149 












Table 1: Review of in vivo studies on the effects of antibiotic treatment on S. Typhimurium dynamics. 160 
A comparative summary of the methodology and conclusions reached in different in vivo studies investigating the 161 
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Despite the growing interest in characterising the effect of antibiotic treatment on different 163 
tissues, quantitative approaches to infer and separately quantify unobserved processes such as 164 
bacterial replication, death, migration and phenotypic switch remain underrepresented. 165 
Additionally, it is now commonly accepted that non-replicating bacterial subpopulations 166 
emerge as a result of antibiotic-exposure. However, the effect of different antibiotic classes, 167 
the tissues of origin of phenotypic variants, and the time point of emergence of these non-168 
growing subpopulations still remain ambiguous. Finally, how bacterial populations recover in 169 
different tissues following antimicrobial withdrawal and how non-growing antibiotic-170 
recalcitrant bacteria regain their replicative capacity during the relapse phase of an infection 171 
are both questions directly relevant to our understanding of bacterial disease recrudescence 172 
underpinning chronic infections. 173 
 174 
An important first step to address these knowledge gaps was taken by Rossi et al. in their ITS-175 
based study of the comparative effects of ampicillin and ciprofloxacin on S. Typhimurium in 176 
vivo [38]. The novel contributions of the study included the use of both a beta-lactam and a 177 
fluoroquinolone antibiotic to directly compare their effects in the same experimental setup, the 178 
study of both the treatment and the relapse phase, the use of clinically relevant doses of 179 
antibiotics after the appearance of symptoms in line with the anticipated clinical response, 180 
instead of supramaximal early therapy, and data collection on 4 different organs involved in 181 
the systemic phase of infection, addressing not only intra- but also inter-organ dynamics. 182 
Finally, unlike previous studies carried at the single bacterial level, Rossi et al. used a bacterial 183 
population-level experimental technique (ITS) in a biological system with well-established 184 
heterogeneity in its dynamics [6, 34-35].  185 
 186 
In this follow-up study, we complement the bacterial population-level outputs of this study by 187 
developing a family of mechanistic mathematical models to identify and quantify the 188 
experimentally unobserved processes of bacterial replication, death, inter-organ migration and 189 
phenotypic switch that collectively underpin the qualitative changes in the net bacterial number 190 
in different organs documented in Rossi et al., 2017 [38]. We perform a simulation-based study 191 
to show that heterogeneities in bacterial phenotypes can be detectable from data collected at 192 
the level of the whole bacterial population. This methodological finding expands the scope of 193 
questions that can be addressed using well-established techniques such as ITS. Motivated by 194 
the well-documented emergence of a persister, antibiotic-recalcitrant bacterial subpopulation 195 
upon antibiotic administration (reviewed in [39]) we consider two models: (1) the single-196 
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phenotype model (SP) assumes a bacterial population with uniform dynamics, with each 197 
biological process described by a single parameter representing the average rate at which the 198 
process occurs, and (2) the dual-phenotype model (DP) assumes that the observed output of 199 
changing bacterial load in tissues is shaped by two bacterial subpopulations with different 200 
dynamics in vivo: one is a replicating, antibiotic-sensitive subpopulation, and the other is a non-201 
replicating, antibiotic-recalcitrant subpopulation [40]. By comparing how well the best model 202 
within each of these two classes of models can recapitulate the experimentally observed 203 
dynamics, we infer that at clinically-relevant doses ampicillin, but not ciprofloxacin, induces a 204 
non-growing antibiotic-recalcitrant bacterial subpopulation.  205 
  206 
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2. Methods  207 
 208 
2.1. Experimental Dataset Structure  209 
 210 
This is a mathematical modelling study using experimental data by Rossi et al., 2017 [38] on 211 
the effect of ampicillin and ciprofloxacin on the within-host dynamics of wild-type S. 212 
Typhimurium in the murine host. Two groups of C57BL/6 mice were inoculated intravenously 213 
with an equiproportionate mix of 8 Isogenic Tagged Strains (ITS) of S. Typhimurium 214 
amounting a total of 1000 colony-forming units (CFU). The infections were allowed to develop 215 
for 72 hours, at which time a proportion of the mice from each group was culled, their organs 216 
harvested (either partially or in totality), homogenised and plated to determine the number of 217 
CFUs per organ/sample. Furthermore, genomic DNA was prepared from the recovered bacteria 218 
and these DNA samples were subjected to next generation sequencing (NGS) in order to 219 
determine the proportion at which each of the 8 ITS was present.  220 
 221 
Of the remaining mice, group A was started with 300 mg/kg ampicillin and group C was put 222 
on a 40 mg/kg ciprofloxacin regimen intraperitoneally (i.p.) per day (maximum recommended 223 
dosage for veterinary treatment of small rodents) [41-42]. Antibiotic treatment was maintained 224 
for 96 hours; a proportion of mice was killed at 24 hour intervals to determine the per organ 225 
total CFU count and ITS composition. In total, data were collected at 4 equally spaced time 226 
points during the antibiotic treatment.  227 
 228 
For the last phase of the study, the antibiotics were stopped and the infection was allowed to 229 
relapse for 54 hours in both groups. Data were collected at 30 and 54 hours post antibiotic 230 
withdrawal.  231 
 232 
2.2. Conceptual Model Structure  233 
 234 
The liver, spleen and mesenteric lymph nodes (MLN) are well-established reservoirs for 235 
Salmonella bacteria [11, 35], while bacteraemia is also a hallmark of systemic salmonellosis. 236 
On the basis of previous biological insight and prior modelling attempts, and acknowledging 237 
that the enteric-systemic interface has not been extensively studied in tandem, we first 238 
considered a general compartmental model allowing all possible connections between the key 239 
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organs for which data were available, and with a single-phenotype bacterial population 240 
characterised by homogeneous dynamics (Figure 1). The parameters governing the transitions 241 
in the model, and mapping to the biological processes in vivo are described in table 2.  242 
 243 
 244 
Figure 1: Generalised single-phenotype model with free inter-organ bacterial migration between the blood, 245 
liver, MLN and spleen, and with intra-organ bacterial death and replication in the all organs.  246 
 247 
As an extension to the single-phenotype model and given the prolonged exposure to antibiotic-248 
induced stressed, we proceeded to formulate a dual-phenotype model (Figure 2). This model 249 
assumes the emergence of a bacterial subpopulation which is non-replicating and survives 250 





Figure 2: The dual-phenotype (DP) model encompasses a phenotypic switch from replicating bacteria 254 
susceptible to killing to non-growing, antibiotic-recalcitrant subpopulations in the liver, spleen and MLN, 255 












m1.2 Bacterial migration from the blood to the liver 
m1.3 Bacterial migration from the blood to the MLN 
m1.4 Bacterial migration from the blood to the spleen 
m2.1 Bacterial migration from the liver to the blood 
m3.1 Bacterial migration from the MLN to the blood 
m4.1 Bacterial migration from the spleen to the blood 
m2.3 Bacterial migration from the liver to the MLN 
m2.4 Bacterial migration from the liver to the spleen 
m3.2 Bacterial migration from the MLN to the liver 
m4.2 Bacterial migration from the spleen to the liver 
m3.4 Bacterial migration from the MLN to the spleen 








m5.6 Bacterial migration from the blood to the liver 
m5.7 Bacterial migration from the blood to the MLN 
m5.8 Bacterial migration from the blood to the spleen 
m6.5 Bacterial migration from the liver to the blood 
m7.5 Bacterial migration from the MLN to the blood 
m8.5 Bacterial migration from the spleen to the blood 
m6.7 Bacterial migration from the liver to the MLN 
m6.8 Bacterial migration from the liver to the spleen 
m7.6 Bacterial migration from the MLN to the liver 
m8.6 Bacterial migration from the spleen to the liver 
m7.8 Bacterial migration from the MLN to the spleen 









k1 Bacterial death in the blood 
k2 Bacterial death in the liver 
k3 Bacterial death in the MLN 
k4 Bacterial death in the spleen 
r1 Bacterial replication in the blood 
r2 Bacterial replication in the liver 
r3 Bacterial replication in the MLN 







s2.6 Switch from P1 to P2 in the liver 
s6.2 Switch from P2 to P1 in the liver 
s3.7 Switch from P1 to P2 in the MLN 
s7.3 Switch from P2 to P1 in the MLN 
s4.8 Switch from P1 to P2 in the spleen 
s8.4 Switch from P2 to P1 in the spleen 
s1.5 Switch from P1 to P2 in the blood 
s5.1 Switch from P2 to P1 in the blood 
 258 
Table 2: Description of parameters used in the mechanistic models 259 
P1 refers to the growing, antibiotic-sensitive bacteria and P2 refers to the non-growing, antibiotic-recalcitrant 260 
bacteria.  261 
 262 
2.3. The modelling framework  263 
 264 
Mathematically, these models (Figures 1 and 2) are translated into multivariate continuous-265 
time Markovian processes [43], with stochastic variables each representing the number of 266 
bacteria in the blood, liver, spleen and MLNs (observed experimental output). The dynamics 267 
of such processes, in particular the probability that the system is at a given state at any particular 268 
time point, can be summarised by the forward Kolmogorov equation, which describes this 269 
probability in terms of the contribution of each of the biological processes included in the 270 
mechanistic model (bacterial replication, killing, migration and phenotypic switch). In this case, 271 
the state refers to a vector consisting of the number of bacteria in all 4 locations at the time 272 
point of interest. Transitions between different states, i.e. any change in the number of bacteria 273 
in any of the tissues of interest over time, are driven by dynamical processes quantified by 274 
parameters, reflecting the rate of development of unobserved bacterial dynamics in time.  275 
 276 
 277 
2.3.1. Summary statistics for cross-distribution comparison 278 
 279 
For a multivariate stochastic system, the overarching forward Kolmogorov equation becomes 280 
analytically intractable for multi-compartmental systems with numerous parameters. To avoid 281 
the step of solving the probability density function characterising the multivariate bacterial 282 
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distribution, we use summary statistics to capture the necessary features of interest. Our models 283 
only incorporate zero-order dynamics, thus the first- (mean numbers of bacteria in each organ) 284 
and second-order (variance-covariance matrix of bacterial numbers in all organs) moments 285 
suffice to describe the distribution [44]. 286 
 287 
2.3.2. Divergence minimisation parameter inference framework 288 
 289 
Here, we solve the mathematical models retrospectively using experimentally measured outputs 290 
(numbers of bacteria per organ) with the aim to estimate the values of unobserved processes, which 291 
correspond to parameters characterising bacterial replication, death, migration and switching to a 292 
non-growing phenotype. To achieve this, we use a likelihood-free inference framework, which 293 
overrides the problem of intractability. As the multivariate distribution is characterised by a set of 294 
first- and second- order moments, it is possible to explore parameter value combinations with the 295 
aim of reaching a distribution that approximates the experimentally observed bacterial distribution 296 
as closely as possible. This is achieved by minimising a quantity (cost function) that cumulatively 297 
expresses the divergences between each experimentally-observed and predicted pair of moments 298 
[44]. In this case we choose the Kullback-Leibler divergence as the cost function to be minimised.  299 
 300 
Parameter inference was performed using the freely available SPEEDI.R package [45] and the 301 
Nelder & Mead [46] optimisation algorithm.  302 
 303 
 304 
2.2.3. Parametric bootstrap for quantification of inference precision and assessment of 305 
model goodness-of-fit 306 
 307 
Goodness-of-fit is a measure of how well a given model captures the experimental data. Here, we 308 
use a parametric bootstrap approach to assess model goodness-of-fit. Using minimum-divergence 309 
moments-based inference, we identify the set of parameters that correspond to first- and second- 310 
order moments and yield the smallest divergence from the observed moments. This set of moments 311 





Using the predicted parameters, we simulate 500 samples of size emulating the number of 315 
observations (10 mice x 8 ITS = 80 or 5 mice x 8 ITS = 40) per time point in the experimental 316 
dataset. For each simulated sample, we calculate the corresponding moments and compare each set 317 
of moments with the predicted moments to obtain a divergence value. We refer to those moments 318 
as simulated moments. If each of the experimental moments fall into their respective distribution 319 
of simulated moments, the goodness-of-fit is adequate and the model can be accepted as plausible.  320 
 321 
We, then, use the simulated moments to anew infer the range of parameter values, which provide 322 
the confidence intervals for our original parameter estimates, and thus serve as a measure of the 323 
inference precision.   324 
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3. Results  325 
 326 
3.1. Simulation study for the detection of heterogeneity in ITS data  327 
 328 
Using infections with mixed inocula comprising ITS it is possible to infer the rates at which 329 
inter- and intra-organ dynamics of infection change over time. However, it has not hitherto 330 
been shown whether data from ITS-based studies can be used to address questions about 331 
heterogeneity in within-host dynamics. Here, we are interested in comparing the performance 332 
of a SP model assuming a single bacterial population with uniform dynamics, and that of a DP 333 
model assuming two bacterial subpopulations with different dynamics, described in section 334 
2.2.  335 
 336 
We performed a simulation-based study to investigate whether bacterial populations with 337 
uniform replication and death dynamics could be reliably distinguished from bacterial 338 
populations composed of both a growing, antibiotic-sensitive subpopulation and a non-growing, 339 
antibiotic-recalcitrant subpopulation, by applying mechanistic models to simulated data from 340 
synthetic ITS-based “experiments”. 341 
 342 
We simulated 10 synthetic datasets with different parameter sets from the dual phenotype DP-343 
model. We then applied both the SP- and DP-models to the 10 synthetic datasets to obtain a 344 
best parameter estimate, and as per 2.2.3, we used a parametric bootstrap approach to generate 345 
500 bootstrapped samples for each of the 10 synthetic datasets under the two models. We 346 
finally performed a pairwise comparison of their goodness-of-fit. 347 
 348 
We used two tools to evaluate the goodness-of-fit of the SP- and DP- models to the synthetic 349 
datasets. The first was the pairwise comparison of the KL divergences; a lower divergence 350 
indicates a better fit between the model and the synthetic data. The second tool was the pairwise 351 
comparison of the similarity between each synthetic dataset and its bootstrapped samples when 352 
the DP- or SP- model was used respectively. To this end, for each of the two models we 353 
obtained the mean value and standard deviation of each moment for the 500 bootstrapped 354 
samples and calculated the number of standard deviations between each true moment value and 355 




For all 10 synthetic datasets simulated from the DP-model, the DP-model gave consistently 358 
lower Kullback-Leibler (KL) divergence values by two orders of magnitude, compared to the 359 
SP-model (shown in Table 3). When applied to DP-data, the bootstrapped samples from the 360 
DP-model were more similar to the original synthetic data than bootstrapped samples from the 361 
SP-model (Figure 3). 362 
 363 
Overall, this simulation study shows that phenotypic heterogeneity at the level of two 364 
subpopulations is detectable from ITS-based data collected at the level of the entire bacterial 365 
population.   366 
 367 
Table 3: Pairwise comparison of KL-divergence values from DP- and SP- model fitting to synthetic datasets 368 
simulated from the DP-model. 369 
 370 
Synthetic dataset index KL divergence from DP- model KL divergence from SP- model 
1 0.0031 0.55 
2 0.0053 1.38 
3 0.0041 0.88 
4 0.0013 0.20 
5 0.0026 1.17 
6 0.0045 0.47 
7 0.0017 0.46 
8 0.0045 0.45 
9 0.0012 0.92 








Figure 3: Comparison of SP- and DP- model performance on synthetic data simulated from the DP-model. 376 
Each of the horizontal panels (1-10) represents the fit between one synthetic dataset and the SP- and DP-models 377 
in blue and red respectively. The blue and red dots represent the number of standard deviations between the 378 
moments of the virtual dataset and the mean value of 500 bootstrapped datasets generated from the best parameter 379 
set in the SP and DP model respectively. The moment indices in the x-axis refer to the 14 means, variances and 380 
covariances used as summary statistics of the ITS distributions in the 4 organs. The number of standard deviations 381 
is always near-zero when the DP-model is applied (red), while consistently higher when the SP- model is applied 382 




3.2. Model Selection  385 
 386 
First, we identified the best-fitting, most parsimonious model from the family of single-387 
phenotype (SP) models, whose structure is shown in Figure 1. Starting from a fully 388 
parameterised model (12 parameters), we fitted sequentially simpler models (nested models) 389 
to data from ampicillin- and ciprofloxacin treated mice day-by-day for 4 days of total treatment 390 
and 2 days post-treatment. For each treatment group, we used the ITS counts per organ at 72 391 
hours post-inoculation as the starting point and the respective ITS counts at 24 hours post-392 
treatment to mark the end of the first day of the antibiotic regimen, and inferred the best 393 
parameter estimate set, as detailed in 2.5.1. We repeated the same inference process to estimate 394 
the parameter values for each time interval separately, totalling 4 time intervals during 395 
antibiotic treatment and 2 during the relapse phase. 396 
 397 
We repeated the same process for the family of DP models, whose structure is shown in Figure 398 
2. The best-fitting models for the SP and DP family of models are comparatively summarised 399 
for each time interval, in the ampicillin- and ciprofloxacin-treated groups. Note that where the 400 
DP model offers no improvement in fitting the experimental data, the best DP model converges 401 
to the best-fitting SP model (Tables 4 and 5 respectively).  402 
 403 







Time Interval (days after 
start of treatment) 
  
Parameters Estimated 





SP Ampicillin 1 k1,k2,k3,k4,r2,r3,r4,m4.2 8 0.66 
DP Ampicillin 1 k1,k2,k3,k4,r2,r3,r4,m4.2 8 0.63 
SP Ampicillin 2 k1,k2,k3,k4,r2,r3, r4 7 0.98 
DP Ampicillin 2 k1,k2,k3,k4,r2,r3, r4 7 0.93 
SP Ampicillin 3 k1,k2,k3,k4,r2r3,r4 7 1.60 
DP Ampicillin 3 k1,k2,k3,k4,r2,r3,r4,m4.8,m8.6 10 0.56 
SP Ampicillin 4 k1,k2,k3,k4,r3,r4, m1.4 7 0.50 
DP Ampicillin 4 k1,k2,k3,k4,r1,r2,r3,r4,m3.7,m4.8 10 0.49 
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SP Ampicillin 5 k2,k3,k4,r1,r2,r3,r4 8 0.58 
DP Ampicillin 5 k2,k6,k7,k8,r1,r2,r6,r7,r8 9 0.12 
SP Ampicillin 6 k1,k2,k3,k4,r1,r2,r3,r4 8 0.73 
DP Ampicillin 6 k1,k2,k6,k7,k8,r1,r2,r6,r7,r8 10 0.39 
 406 
 407 







Time Interval (hours 
after start of 
treatment) 








SP Ciprofloxacin 0-24 k1,k2,k3,k4,r1,r2,r3,r4 8 0.06 
DP Ciprofloxacin 0-24 k2,k4, r2,r4,m3.7,m1.2 6 0.40 
SP Ciprofloxacin 24-48 k1,k2,k3,k4,r1,r2,r3,r4,m2.4 8 2.91 
DP Ciprofloxacin 24-48 k1,k2,k4,r2,r4,m2.4,m3.7,m4.8, m8.6 8 3.40 
SP Ciprofloxacin 48-72 k1,k2,k3,k4,r1,r2,r3,r4,m2.4 9 0.25 
DP Ciprofloxacin 48-72 k1,k2,k3,k4,r1,r2,r3,r4,m1.4,m4.8, 
m2.6,m8.4,m6.2,m7.3 
14 0.33 
SP Ciprofloxacin 72-96 k2,k3,k4,r1,r2,r3,r4 7 0.14 
DP Ciprofloxacin 72-96 k2,k3,k4, r1,r2,r3,r4,m4.8,m8.4, 
m6.2 
10 0.19 
SP Ciprofloxacin 96-126 k2,k3,k4,r1,r2,r3,r4 7 0.54 
DP Ciprofloxacin 96-126 k2,k3,k4,k5,k7,k8,r2,r3,r4,r5,r7,r8, m6.8 13 0.85 
SP Ciprofloxacin 126-140 k1,k2,k3,k4,r1,r2,r3,r4,m2.4 9 0.38 
DP Ciprofloxacin 126-140 k1,k2,k3,k4,r1,r2,r3,r4,m2.4 9 0.38 
 410 
Having identified the best-fitting model from each model family for each of the 6 time intervals 411 
considered in each of the 2 treatment groups, we then assessed whether the divergence of the 412 
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best predicted model from the experimental data can be recapitulated by bootstrapped datasets 413 
simulated from the best parameter set corresponding to the best fitting models. Given that the 414 
DP model family is more complex than the SP model family, we chose the best-fitting DP 415 
model as superior to the best-fitting SP model only if bootstrapped data from the former were 416 
consistently more similar to the experimentally observed data than synthetic data from the SP 417 
model.  418 
 419 
To quantify the similarity between the experimentally observed and bootstrapped data 420 
produced from either the best-fitting SP or the best-fitting DP models, we calculated the first- 421 
and second-order moments for each of the 500 bootstrapped datasets produced from each of 422 
the best-fitting models per time interval per treatment group, followed by the mean and 423 
standard deviation for each of those moments. As illustrated in Figure 4, we then calculated in 424 
standard deviations the distance between the moments from the experimentally observed data 425 
and the mean values for the moments of the bootstrapped samples, similarly to 3.1.  426 
 427 


















Figure 4: Comparison of SP and DP model performance assessing the relationship between model-based 429 
simulations and observed experimental values 430 
The blue and red dots represent the number of standard deviations between the experimentally observed moments 431 
and the mean value of 500 bootstrapped datasets generated from the best parameter set in the SP and DP model 432 
respectively, for each time point. The indices in the x-axis refer to the 14 means, variances and covariances used 433 
as summary statistics of the ITS distributions in the 4 organs. The enumeration of the horizontal panels (1-6) refers 434 
to the number of days after the start of antibiotic treatment. In ampicillin-treated mice, improvement in the model 435 
fit with the DP model is shown by an overall reduction of the number of standard deviations between the 436 
experimentally observed moments and the mean value of 500 parametric datasets, especially during days 2, 3 and 437 




























3.3. SP and DP model comparison in ampicillin-treated mice  464 
 465 
We applied the SP model, described in section 2.2., to the dataset from the ampicillin-treated 466 
group. Upon obtaining the best parameter estimates for each time interval, we simulated 500 467 
bootstrapped datasets to obtain a distribution of values for each of the moments. We expected 468 
that in a well-fitting model, the experimentally observed moments would fall within the 469 
distribution of bootstrapped moments. Figure 5 summarises the results of the fit of the DP- and 470 
SP- model to the experimental data, showing that the DP-model improves the fit of the model 471 




Figure 5: Comparison between the fit of the SP- and DP- models to the experimental data  476 
Each of the boxplots captures the distribution of 500 bootstrapped values for each of the 14 first- and second-477 
order moments, while each red dot represents the value of the same moment from the experimentally observed 478 
data. Improvements can be seen in moments with indices 8, 9, 10, 11 and 14 on day 3, moments with indices 1, 479 
6, 8, 9, 10, 11 and 13 on day 4, and moments with indices 6, 8, 12 and 14 on day 5. The improvement mostly 480 
concerns the variances (indices 4-8) and covariances (indices 8-14).  481 
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3.4. SP model-fit in ciprofloxacin-treated mice 482 
 483 
We then applied the SP-model, described in section 2.2., to the dataset from the ciprofloxacin-484 
treated group and obtained a distribution of values for each of the moments, as in 3.2. Here, we 485 
show that throughout the treatment and relapse phase, the experimentally observed moments 486 
can be recapitulated by simulations from the SP-model given the best set of parameter estimates 487 
(Figure 6). 488 
 
 
Figure 6: Experimental moments in relation to moments from synthetic data using the best-fitting SP 489 











3.5. Intra-organ dynamics during treatment phase  499 
Our models predict that ampicillin and ciprofloxacin exert different effects on intra-organ 500 
bacterial dynamics in terms of their bactericidal and bacteriostatic effects (Figure 7). While in 501 
ciprofloxacin-treated mice, bacterial replication occurs throughout the duration of treatment in 502 
all four organs, ampicillin suppresses bacterial replication, particularly in the blood and in the 503 
late phase of treatment in the spleen and MLN. The occasionally wide confidence intervals in 504 
our estimates are explained by the correlation between replication and killing rates, as shown 505 









Figure 7: 95% confidence intervals of intra-organ replication and killing rates estimated from 500 509 
parametric bootstrapped samples from the best parameter estimates  510 
Panel A comparatively shows the replication rates for ampicillin-treated and ciprofloxacin-treated groups, while 511 
panel B shows the killing rates for the two groups. The dots represent the mean values across 500 parametric 512 
bootstrapped samples from the best parameter estimates, while the bars represent the lower and upper boundaries 513 
of the 95% confidence intervals. The cidal activity in ciprofloxacin-treated mice culminates after 3 days of 514 
treatment, while the static effects of ampicillin peak after 4 days of treatment.  515 
 516 
 517 
Figure 8: Bivariate 95% confidence intervals of intra-organ replication and killing rates (500 bootstrapped 518 
samples) for ciprofloxacin-treated mice 1 day after treatment. 519 
The black, blue and red ellipses illustrate the bivariate 95% confidence interval for replication and killing rate in 520 
the liver, spleen and MLN respectively during day 3 after the start of ciprofloxacin treatment. The large length of 521 
the major axis of the ellipse represents the high correlation between replication and killing parameter estimates, 522 
which accounts for the large confidence intervals seen in Figure 7. Diagonal grid lines indicate net growth rates 523 
(replication rate-killing rate). In the liver and spleen, cidal effects are stronger leading to a negative net growth 524 








3.6. Non-growing subpopulations recalcitrant to antibiotic therapy in ampicillin-treated 531 
mice 532 
In ampicillin-treated mice, the best-fitting DP-model predicts the emergence of a non-growing, 533 
antibiotic-recalcitrant bacterial subpopulation. Our inference shows that this bacterial 534 
subpopulation emerges 48 hours after treatment with ampicillin at varying proportions in 535 
different organs and over time. By 72 hours of treatment, non-growing antibiotic-recalcitrant 536 
bacteria originating from the spleen have migrated to the liver. By 96 hours, the entirety of the 537 
bacterial population in the MLN and spleen have switched to the non-growing, antibiotic-538 
insensitive phenotype, as summarised in Figure 9.  539 
 540 
  541 
Figure 9: Proportion of persister bacteria in the blood, liver, MLN and spleen during ampicillin-treatment 542 
The confidence intervals for the proportion of persister bacteria are expressed as a fraction of total bacterial 543 



















3.7. Dynamics in the relapse phase  546 
Following withdrawal of the 4-days of antibiotic treatment, bacterial infection relapses in both 547 
ampicillin- and ciprofloxacin-treated groups, with positive net growth rates in the first 30 hours 548 
post-withdrawal. In the ampicillin-treated group, the progeny of the growing subpopulation has 549 
a different net growth to that of the non-growing, antibiotic-recalcitrant one in the liver (Liver 550 




Figure 10: 95% confidence intervals of net growth rates (replication - killing rate) during relapse, estimated 555 
from parametric bootstrapped samples based on the best set of parameter estimates 556 
In the ciprofloxacin-treated group with the predicted single bacterial phenotype, the relapse phase is characterised 557 
by positive net growth across all organs, with small fluctuations during the 2 days post ciprofloxacin withdrawal. 558 
In the ampicillin-treated group, the comparison between the net growth rates for the progenitors of the previously 559 
non-growing subpopulation with those of their previously growing counterparts in the liver shows that the former 560 
are consistently higher than the latter. Following bacterial relapse, all organs are repopulated by progenitors of 561 
the previously non-growing, antibiotic-recalcitrant subpopulation.  562 
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To understand what drives the extinction of the previously growing antibiotic-sensitive 563 
population in the liver of ampicillin-treated mice, we compare the killing and replication rates 564 




Figure 11: 95% confidence intervals of intra-organ replication and killing rates estimated from 500 569 
parametric bootstrapped samples from the best parameter estimates during the relapse phase 570 
Panel A comparatively shows the replication rates for ampicillin-treated and ciprofloxacin-treated groups, while 571 
panel B shows the killing rates for the two groups. The dots represent the mean values across 500 parametric 572 
bootstrapped samples from the best parameter estimates, while the bars represent the lower and upper boundaries 573 
of the 95% confidence intervals. In the ampicillin-treated mice, progenitors of the non-growing antibiotic-574 
recalcitrant bacterial reservoir in the liver (Liver (P)) replicate at a higher rate on average compared to the 575 
progenitors of their previously growing counterparts (Liver).  576 
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4.  Discussion 577 
 578 
In the present data-based modelling study, we set out to quantify the effects of ciprofloxacin 579 
and ampicillin on the in vivo dynamics of S. Typhimurium in the murine host. Complementing 580 
previous studies, this is a mathematical modelling study based on data collected at the level of 581 
the bacterial population, using a virulent SL1344 Salmonella strain in C57BL/6 582 
immunocompetent mice that have not been pre-treated with antibiotics. We used data from 583 
mouse infections with two different classes of antibiotics, one beta-lactam and one 584 
fluoroquinolone to directly compare their in vivo effects on the bacterial dynamics in an 585 
intravenous infection of wild-type mice, closely mimicking the systemic phase of non-586 
typhoidal salmonellosis [38].  587 
 588 
The inferential capacity of our mechanistic models is dependent on quantitative signals present 589 
in the experimental data collected by Rossi et al. [38], i.e. changes in the mean number of ITS 590 
copies per organ during time, their variance and their joint variability across all organs 591 
(covariance). Mathematical models can make use of the direction, magnitude and collective 592 
effect of these changes to maximise the insight provided by experimental data, especially if the 593 
changes in the mean numbers, which constitute the primary tool for qualitative inference, are 594 
not strikingly dissimilar. Our simulation study shows that when a single-phenotype model is 595 
applied to data from a dual-phenotype system, there is consistent misestimation of the variances 596 
across all 10 synthetic datasets. In our experimental data, the ill fit of the SP-model during days 597 
3 and 4 of treatment mainly concerns variances and covariances. It, thus, appears that the 598 
quantitative signal allowing us to carry out this inference lies in the second-order moments 599 
(variances, covariances) of the ITS distribution in the organs. 600 
 601 
As a proof-of-concept, we first conducted a simulation-based study to show that mechanistic 602 
models applied to ITS-based data can distinguish between bacterial populations with uniform 603 
and heterogeneous dynamics. Then, we fit a both a SP- and a DP- model to data from 604 
ampicillin- and ciprofloxacin-treated mice. Our best-fitting models suggest that a SP 605 
population can explain the dynamics in ciprofloxacin-treated mice, while the dynamics in 606 
ampicillin-treated mice are further complicated by bacterial phenotypic heterogeneity, best 607 
captured by the DP model with a non-growing, antibiotic-recalcitrant bacterial subpopulation. 608 
Inferences made regarding the rates at which these dynamics develop over time indicate that 609 
while ciprofloxacin acts predominantly via cidal mechanisms, ampicillin has mixed 610 
30 
 
bacteriostatic and bactericidal effects [47]. At the end of ampicillin treatment, surviving 611 
bacteria in the MLN and spleen have adopted a non-replicating, antibiotic-recalcitrant 612 
phenotype; in contrast, the vast majority of surviving bacteria in the ciprofloxacin-treated group 613 
are of the growing, antibiotic-sensitive phenotype. Following antibiotic withdrawal, bacteria 614 
relapse in both the ampicillin- and ciprofloxacin-treated groups of mice. In ciprofloxacin-615 
treated mice, growth rate in the blood, liver and spleen is higher on day 1 post- antibiotic 616 
withdrawal and, subsequently decreases. In ampicillin-treated mice, the liver, spleen and MLN 617 
are repopulated by progenitors of the non-growing antibiotic-recalcitrant bacteria. 618 
 619 
These results can be discussed in the context of previous experimental studies using alternative 620 
observational techniques, including non-phenotypic marker-based techniques [35-36, 46] 621 
fluorescence dilution [34] and peak-to-trough ratio [23]. An in vitro study by Ghooi and Thatte 622 
[26] showed that beta-lactam antibiotics, such as ampicillin, act as both bacteriostatic and 623 
bactericidal agents, due to their concomitant action on bacterial cell wall synthesis inhibition 624 
preventing bacterial replication, and their action on autolysins inducing bacterial death 625 
respectively. McCall et al. [5] introduced the phenomenon of antibiotic-induced stasis to 626 
explain the emergence of a slow- or non-growing bacterial population as a result of exposure 627 
to antibiotics with bacteriostatic effects and proceeded to show that this population cannot be 628 
killed by the same antibiotic class. The inferences made by our best-fitting DP model based on 629 
data from ampicillin-treated mice aligns with these documented in vitro effects of ampicillin 630 
on bacterial growth, as we estimated both strong bacteriostatic effects in the blood and the 631 
organs after 48 hours of treatment, and the emergence of a non-growing, antibiotic-recalcitrant 632 
subpopulation in organs where persisters have previously been reported in vivo [49]. 633 
 634 
In vivo studies using quinolones such as enrofloxacin and ciprofloxacin have highlighted the 635 
emergence of non-growing bacteria that survive treatment in the mesenteric and caecal lymph 636 
nodes, often termed persister cells [6, 34-35, 50]. In these studies, fluoroquinolones were used 637 
very soon after inoculation, and at high doses (8mg/mouse enrofloxacin oral in [34]; 2.4 638 
mg/mouse ciprofloxacin intraperitoneal in [35]). Fluoroquinolones are known to retain their 639 
cidal activity against non-replicating bacteria in vitro, hence additional factors such as the high 640 
antibiotic concentration or low oxygen tension in vivo could be responsible for the emergence 641 




Helaine et al. [34] used a fluorescence dilution (FD) technique to explore the replication history 644 
of individual bacteria during exposure to early, high-dose enrofloxacin in different tissues. 645 
They identified persister bacterial populations in the lymph nodes and spleen. Our modelling 646 
study indicates that the spleen and MLN are indeed the main sites of interest regarding the 647 
emergence of persisters, when mice were treated with ampicillin. However, our model did not 648 
predict this persisting subpopulation in ciprofloxacin-treated mice. This discrepancy could 649 
either be due to the low levels of persisters in this group, which would not affect the ITS 650 
distributions significantly enough to be detected by our model, or due to the differences in the 651 
experimental design of the studies, especially the timing and dose of the fluoroquinolone 652 
therapy, which is known to affect its pharmacokinetic properties [51]. Our findings suggest 653 
that at clinically relevant doses, non-growing “persisters” may not be a universal sequela of 654 
antibiotic treatment, but may be antibiotic-specific, as our SP-model was still adequate to 655 
capture the dynamics in the ciprofloxacin-treated group. Alternatively, the vast majority of 656 
persister bacteria following quinolone exposure may originate from growing instead of non-657 
replicating bacteria [6]. Finally, an important determinant in the apparent lack of consensus in 658 
this field is the significant inherent stochasticity in extinction time and dynamics in vivo during 659 
antibiotic treatment even for large bacterial populations, compounded by host variability [52]. 660 
 661 
As noted, the lymph nodes and spleen have been previously identified as organs that harbour 662 
non-replicating bacteria recalcitrant to antibiotic activity of beta-lactam antibiotics. Our best-663 
fitting DP model for the ampicillin-treated group further suggests that while this group of 664 
persister bacteria originate from bacterial populations originally residing in the spleen and 665 
MLN, they have migratory potential. In particular, these non-growing bacteria migrate from 666 
the spleen to the liver later during the treatment, and interestingly, once in the liver they convert 667 
back to the original phenotype, regaining their replicative capacity, but also their sensitivity to 668 
antibiotic killing. While the trigger of the switch is unknown at this stage, one candidate 669 
mechanism could be the change in bacterial microenvironment due to inter-tissue migration, 670 
particularly the change in occupied host cell type. In a recent in vivo study of splenocytes 671 
infected with S. Typhimurium at the single cell level, Kanvatirth et al. [16] showed that 672 
different host cell types affect not only how easily Salmonellae can replicate or become a target 673 
for killing intracellularly, but also how readily they enter a low metabolic, persister state. In 674 
contrast to the intimate relationship between the liver and the spleen, recalcitrant bacteria 675 
arising in the MLN do not appear to migrate either in the liver or spleen, similar to their growing, 676 
antibiotic-sensitive counterparts in that regard. As a result, the MLN stands in isolation, 677 
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showing distinct dynamics, while the liver and spleen form a network supporting continuous 678 
inter-organ migration.  679 
 680 
During the relapse phase, following withdrawal of antibiotic therapy, bacteria resume growth 681 
and repopulate the liver, spleen and MLN. In the livers of ampicillin-treated mice where the 682 
antibiotic-sensitive and antibiotic-recalcitrant subpopulations co-exit, the former is killed at 683 
higher rates despite replicating at lower rates than the latter, collectively leading to its 684 
extinction. As a result, all three tissues are repopulated by progeny of the antibiotic-recalcitrant 685 
subpopulation.  686 
 687 
Nevertheless, inferences made by our model are subject to three levels of limitations, which 688 
we describe here. Limitations at the level of the experimental data include the absence of 689 
markers of bacterial metabolic activity and uniquely identifiable persister subpopulations. In 690 
terms of our modelling approach, we assumed the simplest case of linear rates describing the 691 
underlying dynamics of the experimental system; although simplifying, our assumption is 692 
justified by dividing the infection timeline into shorter time intervals and making independent 693 
inferences for each, and the fact that we only estimated average rates. We developed and 694 
applied a single- and a dual-phenotype model but did not increase the model complexity further 695 
to include more than two bacterial phenotypes.  Our decision was based on the law of 696 
parsimony, whereby the simplest possible model structure that adequately captures the 697 
observed data is preferred; this reduces the risk of overfitting and model unidentifiability. 698 
Additionally, we pooled the ITS distributions from multiple mice per treatment group per time 699 
point, effectively assuming homogeneous host immune responses. Finally, at the level of 700 
interpreting our results, we have attributed cidal activity to antibiotic effects, ignoring any 701 
baseline immune responses. For the purposes of comparing the effects of the two antibiotics, 702 
and if the assumption that the average baseline immune response between the two groups is 703 
similar, then the differences in the dynamics of two groups are still largely rightly attributable 704 
to the action of the antibiotic in question.  705 
 706 
In summary, in this paper we present an integrated approach between experimental data and 707 
mechanistic mathematical models in a case of immunologically intact, previously untreated 708 
mice infected with S. Typhimurium, treated with either ampicillin or ciprofloxacin, and finally 709 
allowed to relapse. Our study showcases the value of mechanistic mathematical models in 710 
maximising biological insight from experimental data, where previous qualitative inference 711 
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only provides limited information. The additional benefit of our data-driven modelling 712 
approach is making inferences about processes that cannot be or remain challenging to observe 713 
experimentally in a living organism. External validation of our inferential insights would 714 
require in vivo experimental setups that involve groups independently treated with different 715 
antibiotics at clinically relevant regimens, and a reliable marker to discern non-growing, 716 
antibiotic-recalcitrant bacteria at all time points. Ideally, fine-scale data on drug penetration in 717 
different tissues, local drug concentration gradients and host cell uptake would be needed to 718 
determine the exact microenvironment to which bacteria are exposed. Serial sampling of the 719 
bacterial load from the same host would eliminate any variation attributable to within-host 720 
heterogeneity in immune responses.   721 
 722 
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